SEC For	m 4																
FORM 4 UNITED STA					TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
Instruc	tion 1(b).		F					a) of the Secu Investment C			934						
1. Name and Address of Reporting Person [*] Iwicki Mark T					2. Issuer Name and Ticker or Trading Symbol <u>Akero Therapeutics, Inc.</u> [AKRO]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC.,					3. Date of Earliest Transaction (Month/Day/Year) 06/01/2020							Officer (give title Other (specify below) below)					
170 HARBOR WAY, 3RD FLOOR																	
(Street) SOUTH FRANC	94080	_ 4.	Line) X Form filed b									nt/Group Filing (Check Applicable d by One Reporting Person d by More than One Reporting					
(City)	(S	tate)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ear) E	A. Deemo Execution f any Month/Da	Date	, Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Beneficia Owned F	s ally ollowing	6. Owne Form: D (D) or In (I) (Inst	Direct o ndirect B r. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly D (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$25.2	06/01/2020		A		13,000		(1)	05/31/2030	Common Stock	13,000	\$0	13,000		D		

Explanation of Responses:

1. This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.

<u>/s/ Jonathan Young, attorney-in-</u> <u>fact</u> 06/02/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.